糖皮质激素联合小剂量美罗华治疗难治性原发性免疫性血小板减少症的临床研究  

Clinical study of glucocorticoids combined with low-dose of rituximab in the treatment of refractory primary immune thrombocytopenia

作　　者：孟景晔[1] 龙潺[2] 骆子义[1] 朱惠敏[1] 

机构地区：[1]广东省深圳市第三人民医院血液科,518112 [2]惠州市第一人民医院血液科

出　　处：《临床医学》2017年第2期21-22,共2页Clinical Medicine

摘　　要：目的观察糖皮质激素联合小剂量美罗华治疗难治性原发免疫性血小板减少症(ITP)的疗效和不良反应。方法将56例难治性免疫性血小板减少性紫癜患者随机分为两组,治疗组口服地塞米松40 mg/d,连续4 d;美罗华剂量为100 mg/周,连续4周。对照组口服地塞米松40 mg/d,连续治疗4 d后停药1周,再重复治疗4 d。结果治疗组总反应率为82.1%,完全反应率为53.6%;对照组总反应率为35.7%,完全反应率为17.9%,两组比较差异有统计学意义(P<0.05)。结论糖皮质激素联合小剂量美罗华治疗难治性原发性免疫性血小板减少症疗效确切,可作为治疗的有效手段。Objective To evaluate the efficacy and safety of glucocorticoids combined with low-dose of rituximab for re- fractory primary immune thromboeytopenia（ITP）. Methods Fifty-six refractory ITP patients were randomly divided into treatment group and control group. The patients in treatment group received dexamethasone 40 mg/d on days 1 -4, followed by rituximab 100 mg on days 7, 14, 21,28. The patients in control group received dexamethasone 40 mg/d on days 1 -4, discontinued one week, and then repeated the treatment for four days. Results The overall response rate in the treatment group was 82. 1% , and the complete response rate was 53.6%. The overall response rate in the control group was 35.7% , and the complete response rate was 17.9%. The differences were significant（ P 〈 0. 05 ）. Conclusion The therapeutic effect of glucocorticoids combined with low dose of rituximab on refractory ITP is good, and can be used as an effective way of treatment.

关 键 词：糖皮质激素 美罗华 免疫性血小板减少症 难治性 

分 类 号：R558.2[医药卫生—血液循环系统疾病]